Key Event Details
The Office of the Regional Director, Western Region, Government of India, Ministry of Corporate Affairs returned the company's application for fast-track approval of the scheme of merger of KIA Health Tech Private Limited (Wholly Owned Subsidiary) with Rubicon Research Limited (Parent Company). The order was dated November 6, 2026, and was received by the company on November 13, 2026.
Reasons for Return of Application
The merger application was returned due to failure to meet two specific conditions:
- Shareholder approval: The scheme was approved by 88.65% of total shareholders versus the required 90% threshold (though it was approved by 99.44% of shareholders who actually voted)
- Creditor approval: The scheme was approved by unsecured creditors representing 71.83% of the total value of unsecured creditors versus the required 90% threshold. All responding creditors consented to the merger, but insufficient creditors responded.
Financial and Operational Impact
The disclosure explicitly states:
- Expected financial implications: None
- No penalties or restrictions imposed
- No aberrations/non-compliances identified by the authority
- The scheme is an internal restructuring initiative with no material impact on business operations
- KIA Health Tech Private Limited presently has no operations
Company Actions
Rubicon Research Limited is evaluating various options including pursuing the merger through the regular NCLT process instead of the fast-track route.
Additional Information
The disclosure includes Annexure A with detailed particulars as required under Regulation 30(13) of SEBI Listing Regulations, covering all mandatory disclosure points including type of communication, date of receipt, authority, summary of contents, and company response.